文献速递慢性肾脏病

罗沙司他治疗非透析依赖性慢性肾脏病贫血的3期研究

Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.
PubMed 文献 · Kidney Int Rep · 2021-04-17

这项在日本非透析依赖性慢性肾脏病(NDD CKD)患者中进行的3期、活性对照、多中心、部分随机、开放标签研究显示,罗沙司他与达依泊汀α(DA)相比在维持血红蛋白(Hb)水平方面非劣效。罗沙司他组与DA组第18-24周平均Hb较基线变化的LS均值差异为-0.07 g/dl(95%CI下限-0.23 g/dl),确认非劣效性。罗沙司他维持Hb在10-12 g/dl,安全性特征与既往研究一致。

要点

  • 罗沙司他在NDD CKD患者中维持Hb在10-12 g/dl,与达依泊汀α相比非劣效。
  • 第18-24周平均Hb较基线变化的LS均值差异为-0.07 g/dl(95%CI下限-0.23 g/dl)。
  • 常见治疗中出现的不良事件包括鼻咽炎、CKD、高钾血症和高血压。

核心结论

  • 罗沙司他在NDD CKD患者中维持Hb在10-12 g/dl,且非劣效于达依泊汀α。

研究设计与样本

  • 3期、活性对照、多中心、部分随机、开放标签研究,在日本NDD CKD患者中进行。
  • 共334例患者被随机或分配接受治疗:罗沙司他(比较组)132例,达依泊汀α(比较组)131例,罗沙司他(参考组)71例。

主要发现

  • 罗沙司他(比较组)与达依泊汀α(比较组)第18-24周平均Hb较基线变化的LS均值差异为-0.07 g/dl,95%CI下限为-0.23 g/dl,确认非劣效性。
  • 24周治疗期间常见治疗中出现的不良事件(任一组≥3%)包括鼻咽炎、CKD、高钾血症和高血压。

临床怎么用

  • 对于NDD CKD贫血患者,罗沙司他可作为一种口服治疗选择,维持Hb在10-12 g/dl。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease (CKD) who were not on dialysis (NDD). METHODS: This was a phase III, active-controlled, multicenter, partially randomized, open-label study in Japanese patients with NDD CKD. Patients who had used recombinant human erythropoietin or darbepoetin alfa (DA) before conversion were randomized to roxadustat or DA (comparative arms). Patients who had used epoetin beta pegol before conversion were allocated to roxadustat (reference arm). The primary endpoint was change in average hemoglobin (Hb) level from baseline during the evaluation period (Weeks 18-24). Longer term efficacy and safety were evaluated in roxadustat-treated patients over 52 weeks. RESULTS: In this study, 334 patients were randomized/allocated to receive treatment (n = 132, roxadustat [comparative]; n = 131, DA [comparative]; n = 71, roxadustat [reference]). The estimated difference between the roxadustat (comparative) and DA (comparative) groups in the least squares mean of change of average Hb levels of Weeks 18 to 24 from baseline was -0.07 g/dl, with the lower limit of 95% confidence interval of -0.23 g/dl, thereby confirming the noninferiority of roxadustat to DA. Common treatment-emergent adverse events (≥3% of patients in any treatment group) observed during the 24-week treatment period included nasopharyngitis, CKD, hyperkalemia, and hypertension. CONCLUSION: Roxadustat maintained Hb within 10 to 12 g/dl in NDD CKD patients and was noninferior to DA. The safety profiles observed in this study are consistent with previous studies performed in this patient population.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Akizawa T, Iwasaki M, Otsuka T, et al. Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD. Kidney Int Rep. 2021. PMID: 34307976. doi:10.1016/j.ekir.2021.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。